WCLC 2026 presentations spotlight fresh survival gains and improved treatment tolerability across RYBREVANT EGFR-mutated lung cancer regimens

Johnson & Johnson will present new data on RYBREVANT and RYBREVANT FASPRO at the International Association for the Study of Lung Cancer’s 2026 World Conference on Lung Cancer, contributing to meaningful progress in care for patients with EGFR mutated non small cell lung cancer. The presentations will include final overall survival results for RYBREVANT plus chemotherapy in patients with EGFR exon 20 insertion mutated NSCLC, selected to appear in the Presidential Symposium, along with new findings showing low rates of key treatment related events with RYBREVANT FASPRO and prophylactic strategies in patients with common EGFR mutations, offering insight intended to inform clinical practice and improve the overall treatment experience.

Perspectives on key data at WCLC

Yusri Elsayed, M.D., M.H.Sc., Ph.D., global therapeutic area head of oncology at Johnson & Johnson, said the evidence behind RYBREVANT is shifting expectations around survival and treatment experience for people living with EGFR mutated non small cell lung cancer, delivering outcomes that once seemed unattainable. He said the data being presented at WCLC underscore the clinical potential of RYBREVANT and its dual targeting of EGFR and MET, as the company continues developing new approaches aimed at helping more patients live longer and gain meaningful benefit from treatment.

Key data highlighting the long term impact and continued development of RYBREVANT and RYBREVANT FASPRO include:

• Final overall survival analysis from the Phase 3 PAPILLON study, selected for the Presidential Symposium, evaluating first line RYBREVANT plus chemotherapy in NSCLC with EGFR exon 20 insertions
• Extended follow up data from the Phase 2 COPERNICUS study evaluating RYBREVANT FASPRO plus LAZCLUZE  alongside prophylactic strategies in first line EGFR mutated NSCLC
• Updated findings from the Phase 2 PALOMA-2 study evaluating first line RYBREVANT FASPRO plus LAZCLUZE in EGFR mutated NSCLC
• Real-world evidence spanning the EGFR treatment journey, including how resistance mechanisms affect overall survival in first line treatment

---

---

Related Topics and Keywords

egfr mutated lung cancer, Johnson and Johnson, lung cancer, rybrevant, RYBREVANT®'s EGFR-mutated lung cancer, WCLC 2026